(Downloads - 0)
For more info about our services contact : help@bestpfe.com
Table of contents
CHAPTER 1: HYPOTHSES AND OBJECTIVES
CHAPTER 2 : INTRODUCTION
2.1. Cardiovascular diseases
2.1.1 Risk factors of cardiovascular disease
2.1.1.1. Principal risk factors of cardiovascular disease
2.1.1.2. Predisposing risk factors of cardiovascular disease
2.1.1.3. Potential risk factors of cardiovascular disease
2.1.2. Pathophysiology of cardiovascular diseases
2.1.3 Systems biology and the network of gene-environment interactions of cardiovascular diseases
2.2. Metabolic syndrome
2.2.1. Metabolic syndrome historical mirror
2.2.2 Metabolic syndrome increases the risk of atherosclerosis and T2D
2.2.3. Metabolic syndrome risk factors
2.2.4. Proposed metabolic syndrome’s pathophysiologies
2.2.4.1. Explanatory molecular pathways disturbance underlying of MetS
2.2.5. Endothelial dysfunction and metabolic syndrome
2.2.6. Inflammation role in the pathophysiology of metabolic syndrome
2.2.7. Genetic and ethnic variations in metabolic syndrome
2.2.8. Genetic heritability of metabolic syndrome related components
2.2.9. Diagnostic criteria of metabolic syndrome
2.2.10. Metabolic syndrome Epidemiology in the world
2.3. Vasculogenesis and angiogenesis
2.3.1. Vascular system in embryonic period
2.3.1.1. Vasculogenesis steps and angiogenesis forms
2.3.2 Angiogenesis regulatory factors
2.3.3. Vascular endothelial growth factor (VEGF)
2.3.3.1. VEGF brief history
2.3.3.2. VEGF family members, related receptors and mode of action
2.3.3.3. VEGFA gene, related isoforms and proteins
2.3.3.4. VEGF heritability
2.3.3.5. Regulation of VEGF expression
2.3.3.5.1. VEGF producing and expressing cells and tissues
2.3.3.5.2. VEGF expression influencing factors
2.3.3.5.3. VEGF transcription factors
2.3.3.6 VEGF activities
2.3.3.6.1 VEGF functions in angiogenesis and lymphangiogenesis
2.3.3.6.2. Influence of VEGF on bone marrow cells and hematopoiesis
2.3.3.6.3. Increasing of vascular permeability and hemodynamic effects
2.3.3.7. Clinical significance of VEGF
2.3.3.7.1. Wide implications of VEGF, from physiological circumstances to pathological conditions
2.3.3.7.2. Wound healing
2.3.3.7.3. Diabetes and its related complications
2.3.3.7.4. Hypertension
2.3.3.7.4.1. Essential hypertension
2.3.3.7.4.2. Pre-eclampsia (pregnancy-induced hypertension)
2.3.3.7.5. Diabetic nephropathy
2.3.3.7.6. Obesity and metabolic syndrome
2.3.3.7.7 Atherosclerosis
2.3.3.8. VEGF gene single nucleotide polymorphisms and associated diseases
CHAPTER3: RESULTS AND DISCUSSION
3.1. Influences of pre-analytical variables on VEGF gene expression and circulating concentrations
3.2. Identification of cis- and trans-Acting Genetic Variants Explaining Up to Half the Variation in Circulating Vascular Endothelial Growth Factor Levels
3.3. Associations of VEGF with adhesion and inflammation molecules in a healthy population
3.4. Associations of vascular endothelial growth factor cis and trans-acting genetic variants with metabolic syndrome and its related components
3.5. High Prevalence of Metabolic Syndrome in Iran in Comparison with France
CHAPTER 4: GENERAL DISCUSSION
CHAPTER 5: CONCLUSION AND PERSPECTIVES
SYNTHESE EN FRANÇAIS
AVANT-PROPOSE
CHAPITRE F1: HYPOTHESE ET OBJECTIFS
CHAPITRE F2 : RESULTATS ET DISCUSSION
F.2.1. Influence des variables pré-analytique sur l’expression génétique et les taux de VEGF circulant
F.2.2. Identification de variants génétiques agissant en cis et trans expliquant jusqu’ à la moitié de la variation des taux circulants du facteur de croissance de l’endothélium vasculaire
F.2.3. Association du VEGF à des molécules d’adhésion et de l’inflammation dans une population saine
F.2.4. Association des variants génétiques du VEGF agissant en cis et en trans avec le syndrome métabolique et ses composants
F.2.5. Prévalence élevée du syndrome métabolique en Iran en comparaison avec la France
CHAPITRE F3 : DISCUSSION GЀNЀRALE
CHAPITRE F4 : CONCLUSION ET PRESPECTIVES
REFERENCES
